Association of DNA damage response (DDR) gene mutations (mts) and response to neoadjuvant cisplatin-based chemotherapy (chemo) in muscle-invasive bladder cancer (MIBC) patients (pts) enrolled onto SWOG S1314.

被引：0
|
作者：
Iyer, Gopa
Tangen, Catherine
Sarfaty, Michal
Regazzi, Ashley Marie
Lee, I-Ling C.
Choi, Woonyoung
Dinney, Colin P. N.
Flaig, Thomas W.
Thompson, Ian M.
McConkey, David James
Rosenberg, Jonathan E.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA USA
[3] Davidoff Canc Ctr, Rabin Med Ctr, Petah Tiqwa, Israel
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[5] Johns Hopkins, Johns Hopkins Greenberg Bladder Can Inst, Dept Urol, Baltimore, MD USA
[6] Univ Colorado, Canc Ctr, Aurora, CO USA
[7] Childrens Hosp San Antonio, San Antonio, TX USA
[8] Johns Hopkins Greenberg Bladder Canc Inst, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4522
引用
收藏
页数：1
相关论文
共 50 条
  • [31] BRCA1, RAP80, and AEG-1 mRNA expression in resectable muscle-invasive bladder cancer (MIBC) patients (p) treated with neoadjuvant cisplatin-based chemotherapy
    Font Pous, Albert
    Celiz, Pamela
    Taron, Miquel
    Chaib, Iman
    Luis Gago, Jose
    Mendez, Pedro
    Javier Sanchez, Jose
    Etxaniz, Olatz
    Cechini, Luis
    Pardo, Nuria
    Sanchez, Belen
    Luis Cuadra, Jose
    Valverde, Ivana
    Buisan, Oscar
    Ibarz, Luis
    Rosell, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
    Miron, Benjamin
    Hoffman-Censits, Jean H.
    Anari, Fern
    O'Neill, John
    Geynisman, Daniel M.
    Zibelman, Matthew R.
    Kutikov, Alexander
    Viterbo, Rosalia
    Greenberg, Richard E.
    Chen, David
    Lallas, Costas D.
    Trabulsi, Edouard J.
    Alpaugh, R. Katherine
    Dulaimi, Essel
    Golemis, Erica A.
    Uzzo, Robert
    Ross, Eric A.
    Plimack, Elizabeth R.
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (04): : 544 - 547
  • [33] Potential utility of a 4-marker immunohistochemistry panel to predict response to cisplatin-based neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: a single-center preliminary experience
    Morselli, Simone
    Campi, Riccardo
    Gacci, Mauro
    Sebastianelli, Arcangelo
    Fattorini, Caterina
    Villari, Donata
    Carini, Marco
    Minervini, Andrea
    Serni, Sergio
    Raspollini, Maria R.
    MINERVA UROLOGY AND NEPHROLOGY, 2021, 73 (04): : 424 - 427
  • [34] Development of a MRI-Based Radiomics Nomogram for Prediction of Response of Patients With Muscle-Invasive Bladder Cancer to Neoadjuvant Chemotherapy
    Zhang, Xinxin
    Wang, Yichen
    Zhang, Jin
    Zhang, Lianyu
    Wang, Sicong
    Chen, Yan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [35] Association between the Absolute Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy in Muscle-invasive Bladder Cancer
    Leibowitz-Amit, R.
    Israel, A.
    Gal, M.
    Atenafu, E. A.
    Symon, Z.
    Portnoy, O.
    Laufer, M.
    Dotan, Z.
    Ramon, J.
    Avni, D.
    Fridman, E.
    Berger, R.
    CLINICAL ONCOLOGY, 2016, 28 (12) : 790 - 796
  • [36] Association of molecular subtypes with pathologic response in a phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy (NAC) for localized, muscle-invasive bladder cancer (SWOG S1314; NCT02177695).
    Lerner, Seth P.
    McConkey, David James
    Tangen, Catherine
    Meeks, Joshua J.
    Flaig, Thomas W.
    Hua, Xing
    Daneshmand, Siamak
    Alva, Ajjai Shivaram
    Lucia, M. Scott
    Theodorescu, Dan
    Goldkorn, Amir
    Milowsky, Matthew, I
    Choi, Woonyoung
    Bangs, Richard Carlton
    Gustafson, Daniel
    Thompson, Ian Murchie
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy
    Hiromi Murasawa
    Takuya Koie
    Chikara Ohyama
    Hayato Yamamoto
    Atsushi Imai
    Shingo Hatakeyama
    Takahiro Yoneyama
    Yasuhiro Hashimoto
    Ikuya Iwabuchi
    Masaru Ogasawara
    Toshiaki Kawaguchi
    International Journal of Clinical Oncology, 2017, 22 : 159 - 165
  • [38] OUTCOME TO NEOADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN RESECTABLE MUSCLE-INVASIVE BLADDER CANCER (MIBC) PATIENTS (P) ACCORDING TO EXPRESSION LEVELS OF BRCA1, RAP80, AND AEG-1
    Pardo, N.
    Celiz, P.
    Font, A.
    Taron, M.
    Chaib, I.
    Mendez, P.
    Sanchez, J. J.
    Sanchez, B.
    Cuadra Urteaga, J. L.
    Rosell, R.
    ANNALS OF ONCOLOGY, 2012, 23 : 266 - 266
  • [39] The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy
    Murasawa, Hiromi
    Koie, Takuya
    Ohyama, Chikara
    Yamamoto, Hayato
    Imai, Atsushi
    Hatakeyama, Shingo
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Iwabuchi, Ikuya
    Ogasawara, Masaru
    Kawaguchi, Toshiaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (01) : 159 - 165
  • [40] DNA damage repair (DDR) gene mutations (mut) are predictors of response to platinum-based chemotherapy in advanced pancreatic cancer (PC) patients (pts).
    Verdaguer, Helena
    Guardiola-Fernandez, Magda
    Mancuso, Francesco M.
    Acosta, Daniel
    Bux, Elvira
    Hernando, Jorge
    Diez, Marc
    Laquente, Berta
    Baraibar, Iosune
    Ros, Javier
    Garcia, Alejandro
    Matito, Judit
    Martin, Agatha
    Sierra, Alexandre
    Villacampa, Guillermo
    Molero, Cristina
    Miquel, Josep M.
    Vivancos, Ana
    Dienstmann, Rodrigo
    Macarulla, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345